


Abstract

The present invention relates to compounds of the formula I in which substituents R^2 and R^3 are arranged in trans-configuration:




(1)

wherein:


R^1 is H or C1-C6 alkyl; C3-C7 cycloalkyl;

R^2 is phenyl, optionally substituted with 1 to 5 substituents independently selected from the group comprising OH, C1-C6 -alkyl, halogen, nitro, cyano, SH, SR^4 , trihalo-C1-C6-alkyl, C1-C6 -alkoxy and phenyl, wherein R^4 is C1-C6 alkyl;


R^3 is phenyl substituted with OR^5 wherein R^5 has the formula (II), (III) or (IV)



(II)



(III)



(IV)

wherein Y is chosen from NHR^4 , NR^4_2 , $NHCO R^4$, $NHSO_2 R^4$, $CONHR^4$, $CONR^4$, $CONR^4_2$, $COOH$, $COOR^4$, $SO_2 R^4$, SOR^4 , $SONHR^4$, $SONR^4_2$, a C3-C7 heterocyclic ring, saturated or unsaturated, containing one or two heteroatoms independently selected from the group consisting of O, S and N, optionally being substituted with 1 to 3 substituents independently selected from the group comprising H, OH, halogen, nitro, cyano, SH, SR^4 , trihalo-C1-C6-alkyl, C1-C6-alkyl and C1-C6 -alkoxy, preferably NHR^4 , NR^4_2 , or a nitrogen heterocycle, wherein R^4 is as defined above, and the esters, ethers, and salts of the compounds of formula I, optionally along pharmaceutically acceptable excipients, a process for the preparation of the same, and a method of preventing and/or treating estrogen-related disease conditions in a subject using compounds of formula 1, or its salts, optionally along with pharmaceutically acceptable excipients.